In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Drug treatment with beta-blockers and long-term outcome in patients with takotsubo syndrome: results from the takotsubo italian network

Session Blockbusters from the Young in myocardial and pericardial disease

Speaker Angelo Silverio

Event : ESC Congress 2019

  • Topic : valvular, myocardial, pericardial, pulmonary, congenital heart disease
  • Sub-topic : Tako-Tsubo Cardiomyopathy
  • Session type : Abstract Sessions

Authors : A Silverio (Salerno,IT), R Citro (Salerno,IT), E Bossone (Naples,IT), M Bellino (Salerno,IT), C Zito (Messina,IT), G Provenza (Salerno,IT), C Prota (Benevento,IT), G Iuliano (Salerno,IT), I Radano (Salerno,IT), MV Polito (Salerno,IT), C Baldi (Salerno,IT), G Novo (Palermo,IT), F Antonini-Canterin (Pordenone,IT), G Galasso (Salerno,IT), G Parodi (Sassari,IT)

A. Silverio1 , R. Citro1 , E. Bossone2 , M. Bellino1 , C. Zito3 , G. Provenza1 , C. Prota4 , G. Iuliano1 , I. Radano1 , M.V. Polito1 , C. Baldi1 , G. Novo5 , F. Antonini-Canterin6 , G. Galasso1 , G. Parodi7 , 1University Hospital “San Giovanni di Dio e Ruggi d'Aragona”, Department of Cardiology - Salerno - Italy , 2Cardarelli Hospital, Department of Cardiology - Naples - Italy , 3University of Messina, Division of Cardiology - Messina - Italy , 4Fatebenefratelli Hospital of Benevento, Department of Cardiology - Benevento - Italy , 5University of Palermo, Department of Cardiology - Palermo - Italy , 6Sacile Hospital, Division of Rehabilitation Cardiology - Pordenone - Italy , 7University Hospital of Sassari, Division of Interventional Cardiology - Sassari - Italy ,

On behalf: Takotsubo Italian Network investigators

Tako-Tsubo Cardiomyopathy

European Heart Journal ( 2019 ) 40 ( Supplement ), 3095

Background: Although generally considered a benign disease, Takotsubo syndrome (TTS) has recently been associated to a substantially comparable long-term outcome than acute coronary syndrome (ACS). The use of beta-blockers (BB) has been advocated in these patients for secondary prevention after the index event, considering the presumed role of catecholamine in TTS pathophysiology. However, the effect of BB on long-term outcome remains controversial due to the paucity of data and the lack of evidence from randomized studies.

Purpose: To investigate the impact of BB therapy on long-term outcome in patients with TTS.

Methods: The study included all TTS patients enrolled in the Takotsubo Italian Network multicenter registry. Patients were divided in two study groups according to the BB therapy after discharge. The following major adverse cardiac events (MACE) were assessed at the longest available follow-up: cardiac death, TTS recurrence, rehospitalization for cardiac cause, acute or worsening heart failure (HF) and ACS. Also, the composite of cardiac death and rehospitalization as well as the overall MACE were analyzed

Results: The study population included 548 patients (mean age 68.7±11.4 years; 44 males, 8%). Among them, BB treatment was reported in 368 (BB group, 67.2%) and 180 (no-BB group, 32.8%) patients, respectively. The baseline clinical characteristics were substantially comparable among groups with the only exception of COPD, which was prevalent in the no-BB group (10.3% vs 21.7%, p=0.001).

During follow-up (median 18 months 25–75% c.i. 6–29), TTS recurrence was reported in 26 patients (4.7%), ACS in 10 (1.8%), acute or worsening HF in 39 (7.1%), cardiac hospitalization in 71 (13.0%) and cardiac death in 18 (3.3%). The rate of TTS recurrence and ACS was comparable between groups. Conversely, no-BB patients experienced more frequently acute or worsening HF (5.4% vs 10.6%, p=0.034), cardiac rehospitalization (10.9% vs 17.2%, p=0.042) and cardiac death (1.9% vs 6.1, p=0.018) than BB patients. Therefore, the MACE composite endpoint was significantly prevalent in the no-BB group (12.0% vs 20.6%, p=0.010).

Kaplan-Meier curves for the composite of cardiac death and rehospitalization showed a statistically lower survival in the no-BB patients compared to the BB group (p=0.006). Moreover, landmark analysis showed a wider survival benefit in the BB patients after 2 years.

Conclusions: Although in absence of a secondary preventive effect on TTS recurrence, BB may improve the long-term cardiac outcome in patients with TTS. Prospective randomized studies are advisable to confirm these findings.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are